Tagged with LG

Mylan - Belgium The generics market in Belgium doesn’t seem to be at the level it deserves to be. Considering that Mylan controls about 14% of the local generics market share, how would you assess the authorities and physicians attitude towards the generic drugs in Belgium? In Belgium, generic drugs are not being…

Sanofi - Belgium Mr Hendrickx, considering that you have been with Sanofi for over a decade, what would you describe as the single most important change in Sanofi’s business model? In essence, it is the diversification of Sanofi into a wide range of business activities. In the past, Sanofi was very successful at…

Eurogentec Belgium Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the business model of the life sciences industry? The pharmaceutical industry is increasingly being under pressure by the rising costs of…

TiGenix - Belgium Mr Bravo, in relation to your previous career in big pharma companies, you have recently made a shift into much smaller entities including Cellerix and TiGenix. What motivated you to make such a dramatic and bold shift in your professional life? I was young and ambitious and despite having a…

Novo Nordisk - Belgium Looking into your background, we see that you have developed your career in the local industry’s top 3 players: Pfizer, AstraZeneca and Novartis until assuming your position as General Manager of Novo Nordisk BeLux less than a year ago. What motivated you to join the company back in 2010 and…

IMS Health Belgium Looking at your background, we see that you have been with IMS for over 12 years. What defines your loyalty to the company? What appeals most to you about IMS? My loyalty to IMS Health lies in the opportunities I have been presented during all these years. Although I have…

Amgen Belgium Can you begin by giving us a brief overview of Amgen in Belgium and tell our readers more about the company’s history here? Compared to other, well-established multinationals Amgen is a relatively young biotechnology company with just over 30 years of experience in the industry. Amgen entered the Belgian market…

FeBelGen Looking into your background, we see that you’ve spent 8 years at pharma.be, where you were advocating the traditional drug producers. What encouraged you to head FeBelGen since 2006, representing the generic and biosimilar drugs industry in Belgium? When I started to head FeBelGen in 2006, my goal/objective was –…

Merck Belgium In your 8 years of experience within the group, how would you classify the competitive advantages derived for the company’s unique familial ownership structure? Due to its history and strong values, Merck certainly does have a specific corporate culture which helps to shape its unique character. This is further enhanced…

MSD Belgium It truly seems that you have pharma in your genes, with a father who successfully developed a migraine drug in addition to your 4 years practicing medicine and now continuing an 18 year career with MSD. What distinguishes MSD as a pharmaceutical company in your opinion? At MSD, we are…

Celgene UK and Ireland Celgene just announced very impressive second quarter results for its global operations, with a 38% increase in revenue partly led by strong growth in Europe. Within the global performance of the company, how would you assess the performance of the UK in 2010/2011? This year has been somewhat of a…

Celgene Hungary The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What are your observations, and how do you expect companies to be adjusting their strategies in this market? The government has a large majority in the parliament since 2 years,…